Last reviewed · How we verify
NCT03029416
Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
Phase 2 trial testing Stereotactic Body Radiation Therapy in Neoplasm Metastasis. Withdrawn.
20 July 2018
Quick facts
| Lead sponsor | Ronald McGarry |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 26 October 2017 |
| Primary completion | 20 July 2018 |
| Estimated completion | 9 August 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stereotactic Body Radiation Therapy — full drug profile →
Conditions studied
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
- Cancer — all drugs for Cancer →
- Radiation Therapy Complication — all drugs for Radiation Therapy Complication →
Sponsor
Ronald McGarry
Who can join
18 and older, any sex, with Neoplasm Metastasis or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
30 Gy single fraction of SBRT for lung metastases will result in comparable oncologic outcomes to 18Gy in three fractions (or dosing to a BED \</-100Gy at the discretion of the radiation oncologist) with respect to disease control and toxicity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03029416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stereotactic Body Radiation Therapy
Trials testing the same drug.
- NCT07156227 — Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell · Phase 1 · not yet recruiting
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07150715 — Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for th · Phase 2 · recruiting
- NCT07150546 — Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. · Phase 1 · recruiting
- NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
Other recruiting trials for Neoplasm Metastasis
Currently open trials in the same condition.
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
- NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
- NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
- NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting
Other Ronald McGarry trials
Trials by the same sponsor.
- NCT01654068 — Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine · NA · terminated
- NCT01657617 — Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03029416 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ronald McGarry
- Last refreshed: 15 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03029416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing